CASI Pharmaceuticals (CASI) AI Stock Analysis

• Market Cap: $29.62M
• Dividend Yield: N/A
• Average Volume (3M): 10.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: -42.92%
• EPS Growth: 26.30%
• Country: US
• Employees: 235
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -2.22
• Shares Outstanding: 13,401,375
• 10 Day Avg. Volume: 5,149
• 30 Day Avg. Volume: 10,225
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1.01
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

CASI Pharmaceuticals' overall score reflects major financial challenges, including declining revenues and high leverage, as the most significant factors. Technical indicators also suggest a bearish trend, while valuation metrics are difficult to assess due to negative earnings. The earnings call did not provide substantial guidance or sentiment to alter the outlook.

CASI Pharmaceuticals Business Overview & Revenue Model

Company Description

CASI Pharmaceuticals (CASI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing unmet medical needs, with an emphasis on the Chinese market. The company's core products include proprietary and in-licensed drugs in the areas of oncology, hematology, and other related fields. CASI leverages its expertise and partnerships to bring cutting-edge treatments to patients, particularly in regions with high demand for advanced healthcare solutions.

How the Company Makes Money

CASI Pharmaceuticals generates revenue primarily through the sales of its proprietary and in-licensed pharmaceutical products. The company capitalizes on its strategic positioning in the Chinese market by leveraging local partnerships and collaborations to enhance the distribution and commercialization of its drugs. Additionally, CASI may engage in licensing agreements, collaborations, and partnerships with other pharmaceutical companies to co-develop or commercialize their products, thereby expanding their revenue streams. The company's focus on high-demand therapeutic areas such as oncology and hematology further supports its potential for revenue generation.

CASI Pharmaceuticals Financial Statement Overview

Summary

CASI Pharmaceuticals faces significant financial challenges, with declining revenues, negative profitability margins, and increasing leverage. The balance sheet shows financial instability, characterized by high liabilities and zero operational cash generation, posing substantial risks for financial sustainability.

Income Statement

CASI Pharmaceuticals shows a declining revenue trend with a significant drop from $43.11M in 2022 to $21.27M TTM. The company is experiencing negative net profit margins, with TTM net income at -$30.35M. Gross profit margin has decreased over the years, and EBIT and EBITDA margins remain negative. These factors suggest challenges in achieving profitability.

Balance Sheet

The company's debt-to-equity ratio has increased due to rising liabilities and decreasing equity, indicating higher leverage. The equity ratio has declined, highlighting reduced financial stability. Return on equity is negative due to persistent losses. The balance sheet reflects financial instability, with high liabilities relative to equity.

Cash Flow

CASI's cash flow statement shows zero operating and free cash flow in TTM, indicating challenges in generating cash from operations. Historical data reveals negative free cash flow, with no evident growth trajectory. The operating cash flow to net income ratio is unfavorable, suggesting liquidity issues.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
21.27M	33.88M	43.11M	30.17M	15.14M	4.13M
	Gross Profit
11.74M	20.05M	27.28M	17.61M	5.63M	196.00K
	EBIT
-36.67M	-25.08M	-26.49M	-35.28M	-33.31M	-39.99M
	EBITDA
-31.07M	-21.54M	-24.07M	-32.75M	-31.35M	-37.43M
	Net Income Common Stockholders
-30.35M	-26.94M	-39.41M	-37.77M	-62.57M	-51.41M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
85.12M	30.77M	51.34M	48.57M	66.37M	54.25M
	Total Assets
113.41M	75.27M	96.23M	138.30M	127.73M	102.63M
	Total Debt
1.50M	21.24M	1.34M	2.17M	1.29M	2.20M
	Net Debt
-82.71M	4.16M	-45.77M	-36.54M	-55.77M	-51.42M
	Total Liabilities
3.95M	51.10M	29.30M	30.34M	24.16M	8.97M
	Stockholders Equity
109.46M	24.16M	44.57M	84.50M	81.54M	73.00M
Cash Flow		Free Cash Flow
0.00	-22.21M	-26.70M	-42.34M	-45.21M	-37.26M
	Operating Cash Flow
0.00	-19.97M	-21.09M	-26.84M	-25.89M	-23.24M
	Investing Cash Flow
0.00	-9.67M	31.16M	-20.69M	-20.72M	-28.06M
	Financing Cash Flow
0.00	-907.00K	-3.27M	29.64M	47.15M	22.05M

CASI Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CASI, the sentiment is Negative. The current price of 2.21 is below the 20-day moving average (MA) of 2.35, below the 50-day MA of 2.53, and below the 200-day MA of 4.62, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 31.82 is Neutral, neither overbought nor oversold. The STOCH value of 27.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CASI.

CASI Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	58 Neutral	$5.90B	268.98	12.21%	―	40.80%	100.62%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
ADAP	44 Neutral	$114.38M	―	-53.54%	―	145.37%	57.01%
CASI	40 Underperform	$29.62M	―	-136.05%	―	-42.92%	26.30%
PDSB	35 Underperform	$53.95M	―	-174.49%	―	―	31.68%